[Role of platelet activating factor in the injury of intestinal immuno-barrier function in young rats]
Related Experiment Video
Updated: Aug 10, 2026
Murine Model of Intestinal Ischemia-reperfusion Injury
Published on: May 11, 2016
Li-Jie Wang1, Chun-Ying Liu, Mei Sun
1Department of Pediatrics, Second Clinical College, China Medical University, Shenyang 110004, China. wlj682002@yahoo.com.cn
Insights
Platelet activating factor (PAF) contributes to intestinal barrier injury during infection. Blocking the PAF receptor with BN52021 in young rats reduced inflammation and preserved secretory IgA levels, indicating potential therapeutic benefits.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Gastrointestinal dysfunction is linked to impaired intestinal barrier function during severe infections.
- Platelet-activating factor (PAF) is implicated in causing intestinal injuries.
Purpose of the Study:
- To investigate the impact of PAF on the intestinal mucosal immuno-barrier function in young rats.
- To evaluate the protective effects of a PAF receptor antagonist against LPS-induced intestinal injury.
Main Methods:
- Young Wistar rats were administered lipopolysaccharide (LPS) with or without the PAF receptor antagonist BN52021.
- Ileum tissues were collected at various time points for histological evaluation and measurement of secretory IgA (sIgA) content.
- Intestinal tissue water content was assessed by calculating the wet/dry weight ratio.
Main Results:
- LPS induced significant intestinal injury, including edema, capillary congestion, and immune cell infiltration.
- The PAF receptor antagonist BN52021 reduced LPS-induced villi edema and partially mitigated the increase in the wet/dry weight ratio.
- LPS challenge markedly decreased intestinal sIgA levels, an effect attenuated by BN52021 administration.
Conclusions:
- PAF plays a significant role in damaging the intestinal immuno-barrier function.
- Both preventive and therapeutic administration of the PAF receptor antagonist BN52021 demonstrated potential in alleviating intestinal injury.
Objective:
Gastrointestinal dysfunction is closely correlated with the destruction of intestinal barrier function induced by serious infection. Platelet activating factor (PAF) may induce intestinal injuries. This study aimed to investigate the effect of PAF on the injury of intestinal mucosal immuno-barrier function in young rats.
Methods:
Eighteen-day-old Wistar rats were randomized to lipopolysaccharide (LPS) (5 mg/kg), LPS plus PAF receptor antagonist and normal saline injection (Control). PAF receptor antagonist BN52021 5 mg/kg was administered before or 30 minutes after LPS injection (pretreatment or treatment). The ileum specimens (n=8) were harvested at 1.5, 3, 6, 24, 48 and 72 hrs after LPS injection. Double antibody-PEG radioimmunoassay was used to determine the secretory IgA (sIgA) content in intestinal mucosa. Hematoxylin and erosin staining was used for histological evaluation. The ratio of wet and dry weight (W/D) of ileum tissues was calculated.
Results:
Intestinal villi edema, capillary congestion, extension of the subepithelial lympho channel, and polymorphonuclear infiltration in enteric cavity were noted in the LPS group at 1.5, 3, 6 and 24 hrs after LPS injection. In the PAF receptor antagonist group only villi edema was found. The W/D ratio in the LPS group was significantly higher than that in the Control group at all time points, but it was slightly reduced by the PAF receptor antagonist pretreatment or treatment. The sIgA content was obviously decreased after 1.5, 3, 6, 24 and 48 hrs of LPS challenge compared with that in the Control group (P < 0.01). It reached to a nadir at 6 hrs (0.15 +/- 0.04 microg/mL). The level of sIgA in the PAF receptor antagonist group was higher than that in the LPS group at each time point. There was no statistical difference in the sIgA level between the PAF receptor pretreatment and treatment groups.
Conclusions:
PAF plays roles in the injury of intestinal immuno-barrier function. Preventive and remedial use of PAF receptor antagonist BN52021 may relieve intestinal injury.
More Related Videos
08:50A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development
Published on: June 24, 2020
04:05A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium
Published on: May 31, 2024
Related Concept Videos
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...